Taysha Gene Therapies (NASDAQ:TSHA - Free Report) had its price target raised by Chardan Capital from $7.00 to $9.00 in a report issued on Thursday,Benzinga reports. They currently have a buy rating on the stock.
A number of other analysts also recently issued reports on TSHA. Cantor Fitzgerald reiterated an "overweight" rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Monday, April 28th. JMP Securities restated a "market outperform" rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Monday, April 28th. Canaccord Genuity Group raised their target price on shares of Taysha Gene Therapies from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Friday, May 16th. Finally, Needham & Company LLC restated a "buy" rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, April 10th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $7.00.
Get Our Latest Report on TSHA
Taysha Gene Therapies Trading Up 2.0%
TSHA stock traded up $0.05 during midday trading on Thursday, hitting $2.76. 1,731,330 shares of the company's stock were exchanged, compared to its average volume of 3,006,702. The company has a market cap of $593.33 million, a PE ratio of 4.37 and a beta of 0.90. Taysha Gene Therapies has a one year low of $1.05 and a one year high of $4.32. The stock's fifty day moving average price is $1.92 and its 200-day moving average price is $1.90. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51.
Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.08) EPS for the quarter, meeting analysts' consensus estimates of ($0.08). Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The company had revenue of $2.30 million for the quarter, compared to analyst estimates of $1.48 million. During the same period in the previous year, the company posted ($0.10) earnings per share. Research analysts predict that Taysha Gene Therapies will post -0.35 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Taysha Gene Therapies
Institutional investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. increased its stake in shares of Taysha Gene Therapies by 2.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company's stock valued at $820,000 after purchasing an additional 11,390 shares during the last quarter. LPL Financial LLC acquired a new stake in shares of Taysha Gene Therapies in the fourth quarter valued at about $104,000. Adage Capital Partners GP L.L.C. bought a new stake in Taysha Gene Therapies in the fourth quarter valued at approximately $8,650,000. Hsbc Holdings PLC increased its position in Taysha Gene Therapies by 65.6% during the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock valued at $36,000 after purchasing an additional 8,076 shares during the period. Finally, Vanguard Group Inc. raised its holdings in Taysha Gene Therapies by 7.8% during the 4th quarter. Vanguard Group Inc. now owns 8,906,764 shares of the company's stock worth $15,409,000 after purchasing an additional 641,305 shares during the last quarter. 77.70% of the stock is currently owned by institutional investors.
Taysha Gene Therapies Company Profile
(
Get Free Report)
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
Further Reading
Before you consider Taysha Gene Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.
While Taysha Gene Therapies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
